What are the specific effects and side effects of Sorafenib/Nexavar?

Sorafenib/Nexavar (Sorafenib) is an oral small molecule targeted drug that is a multi-kinase inhibitor. It was first developed by Bayer and has been approved by many countries and regions for the treatment of advanced hepatocellular carcinoma, renal cell carcinoma and radioactive iodine-refractory thyroid cancer. In the modern tumor treatment system, sorafenib is regarded as one of the pioneering drugs because it successfully applies oral targeted therapy to solid tumors, changing the "one size fits all" pattern of traditional chemotherapy.

From an efficacy perspective, the biggest feature of sorafenib is “multi-target inhibition”. It can block the RAF kinase pathway in tumor cells and interfere with the proliferation of cancer cells; it also inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), etc., cutting off the blood supply that tumor tissues rely on for survival. This dual mechanism not only directly limits the growth of cancer cells, but also indirectly "starves" cancer cells by inhibiting angiogenesis. In hepatocellular carcinoma and renal cell carcinoma, sorafenib can often delay disease progression and buy patients more time to survive. In terms of thyroid cancer, especially in patients who have failed radioactive iodine therapy, sorafenib has also shown unique efficacy, providing a new drug option for refractory thyroid cancer.

In addition to its approved indications, sorafenib also shows potential in the research of blood tumors such as acute myeloid leukemia, mainly by inhibitingFLT3 mutant kinase. Such studies continue to push the application boundaries of sorafenib, making it not only limited to traditional solid tumors, but also gradually extended to hematological diseases.

However, as a targeted drug, sorafenib does not come without costs. Side effects are the focus that must be paid attention to in clinical use, and their main adverse reactions are closely related to their mechanism of action. The most common is hand-foot skin reaction. Patients will experience redness, swelling, pain and even peeling of the palms or soles of the hands. This is related to the drug inhibiting angiogenesis and affecting the peripheral blood supply of the skin. Secondly, diarrhea, fatigue, and loss of appetite are also common side effects, and some patients may also experience weight loss. Because sorafenib acts on vascular-related pathways, the incidence of hypertension also increases significantly, and clinical blood pressure needs to be monitored regularly and timely intervention is required.

In terms of laboratory indicators, sorafenib may cause abnormal liver function, manifested as elevated transaminases or jaundice, which should be especially vigilant for patients with liver cancer. At the same time, changes in thyroid function, risk of bleeding, and delayed wound healing also need attention. Compared with traditional chemotherapy, sorafenib has relatively mild bone marrow suppression, which is one of its advantages of being well tolerated.

It should be pointed out that the occurrence of side effects varies among individuals. Some patients have mild symptoms that can be improved by adjusting the dosage or supportive treatment, while some patients may have to interrupt medication due to serious adverse reactions. Therefore, clinicians often need to find a balance between efficacy and side effects and adjust treatment plans individually.

Reference materials:https://www.nexavar.com/